Comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trials

The objective of this meta-analysis study was to evaluate the comparative efficacy of empagliflozin (25 mg) with placebo in the treatment and management of type 1 diabetes mellitus. This study is a meta-analysis, so an ethical statement is not required. Different databases and individual journal web...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Gillani Syed Wasif, Azhar Anam, Gulam Shabaz Mohiuddin, Gebreigziabher Fithawit Bahran, Rathore Hassaan Anwer
Formato:	article
Lenguaje:	EN
Publicado:	Sciendo 2021
Materias:	meta-analysis type 1 diabetes empagliflozin placebo evidence-based practice Medicine R
Acceso en línea:	https://doaj.org/article/3c3b254bd1ef487aaed0f63d553cfbe4
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:3c3b254bd1ef487aaed0f63d553cfbe4
record_format	dspace
spelling	oai:doaj.org-article:3c3b254bd1ef487aaed0f63d553cfbe42021-12-05T14:11:06ZComparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trials2300-667610.2478/cipms-2021-0024https://doaj.org/article/3c3b254bd1ef487aaed0f63d553cfbe42021-09-01T00:00:00Zhttps://doi.org/10.2478/cipms-2021-0024https://doaj.org/toc/2300-6676The objective of this meta-analysis study was to evaluate the comparative efficacy of empagliflozin (25 mg) with placebo in the treatment and management of type 1 diabetes mellitus. This study is a meta-analysis, so an ethical statement is not required. Different databases and individual journal websites like SCOPUS, Science direct, Cochrane review library etc. were used. The articles were evaluated based on the search and eligibility criteria. A total of five RCTs were incorporated in this meta-analysis. These studies contained a total of 1058 patients, including 526 patients with placebo (or control-treated patients), and 532 patients with empagliflozin (25 mg) treated combination. The mean follow-up time ranged from 7 days to 6 months. Overall, mean reduction in placebo was -0.50% and empa-treated was -0.85%, while the pooled WMD was 3.82 995% CI 1.20 – 5.88, p=0.0001). Regarding urinary glucose excretion, that the pooled WMD was 6.67 (95% CI 4.87-10.14, p=0.001) indicated a significant increase in empa-arm compared to placebo. No heterogeneity was found (I2 – 15.03%). This meta-analysis underlined the therapeutic benefit of empagliflozin as an adjunctive therapy for patients with type 1 diabetes.Gillani Syed WasifAzhar AnamGulam Shabaz MohiuddinGebreigziabher Fithawit BahranRathore Hassaan AnwerSciendoarticlemeta-analysistype 1 diabetesempagliflozinplaceboevidence-based practiceMedicineRENCurrent Issues in Pharmacy and Medical Sciences, Vol 34, Iss 3, Pp 123-129 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	meta-analysis type 1 diabetes empagliflozin placebo evidence-based practice Medicine R
spellingShingle	meta-analysis type 1 diabetes empagliflozin placebo evidence-based practice Medicine R Gillani Syed Wasif Azhar Anam Gulam Shabaz Mohiuddin Gebreigziabher Fithawit Bahran Rathore Hassaan Anwer Comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trials
description	The objective of this meta-analysis study was to evaluate the comparative efficacy of empagliflozin (25 mg) with placebo in the treatment and management of type 1 diabetes mellitus. This study is a meta-analysis, so an ethical statement is not required. Different databases and individual journal websites like SCOPUS, Science direct, Cochrane review library etc. were used. The articles were evaluated based on the search and eligibility criteria. A total of five RCTs were incorporated in this meta-analysis. These studies contained a total of 1058 patients, including 526 patients with placebo (or control-treated patients), and 532 patients with empagliflozin (25 mg) treated combination. The mean follow-up time ranged from 7 days to 6 months. Overall, mean reduction in placebo was -0.50% and empa-treated was -0.85%, while the pooled WMD was 3.82 995% CI 1.20 – 5.88, p=0.0001). Regarding urinary glucose excretion, that the pooled WMD was 6.67 (95% CI 4.87-10.14, p=0.001) indicated a significant increase in empa-arm compared to placebo. No heterogeneity was found (I2 – 15.03%). This meta-analysis underlined the therapeutic benefit of empagliflozin as an adjunctive therapy for patients with type 1 diabetes.
format	article
author	Gillani Syed Wasif Azhar Anam Gulam Shabaz Mohiuddin Gebreigziabher Fithawit Bahran Rathore Hassaan Anwer
author_facet	Gillani Syed Wasif Azhar Anam Gulam Shabaz Mohiuddin Gebreigziabher Fithawit Bahran Rathore Hassaan Anwer
author_sort	Gillani Syed Wasif
title	Comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trials
title_short	Comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trials
title_full	Comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trials
title_fullStr	Comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trials
title_full_unstemmed	Comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trials
title_sort	comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trials
publisher	Sciendo
publishDate	2021
url	https://doaj.org/article/3c3b254bd1ef487aaed0f63d553cfbe4
work_keys_str_mv	AT gillanisyedwasif comparativeefficacyofempagliflozinversusplacebointhetreatmentoftype1diabetesmellitusametaanalysisofrandomizedcontrolledtrials AT azharanam comparativeefficacyofempagliflozinversusplacebointhetreatmentoftype1diabetesmellitusametaanalysisofrandomizedcontrolledtrials AT gulamshabazmohiuddin comparativeefficacyofempagliflozinversusplacebointhetreatmentoftype1diabetesmellitusametaanalysisofrandomizedcontrolledtrials AT gebreigziabherfithawitbahran comparativeefficacyofempagliflozinversusplacebointhetreatmentoftype1diabetesmellitusametaanalysisofrandomizedcontrolledtrials AT rathorehassaananwer comparativeefficacyofempagliflozinversusplacebointhetreatmentoftype1diabetesmellitusametaanalysisofrandomizedcontrolledtrials
_version_	1718371415232610304

Comparative efficacy of empagliflozin versus placebo in the treatment of type 1 diabetes mellitus: a meta-analysis of randomized controlled trials

Ejemplares similares